New Delhi, Nov 8 (PTI) Zydus Lifesciences on Tuesday said it has received approval from the US health regulator to market blood pressure lowering drug Bisoprolol Fumarate and Hydrochlorothiazide tablets in the American market.

The company has received approval from the US Food and Drug Administration (USFDA) to market the generic medication in multiple strengths, the Ahmedabad-based drug maker said in a statement.

Also Read | Uttarakhand Sthapna Diwas 2022 Date: Know the History & Significance of Uttarakhand Divas That Marks the State Foundation Day.

Bisoprolol Fumarate and hydrochlorothiazide combination is indicated to treat high blood pressure (hypertension).

The drug will be manufactured at the company's formulation manufacturing facility at Ahmedabad SEZ, the company said.

Also Read | India in Stable Economic Situation, Growth Momentum Is Good, Says CEA V Anantha Nageswaran.

As per IQVIA MAT September 2022 data, Bisoprolol Fumarate and Hydrochlorothiazide tablets had annual sales of USD 27.1 million in the United States.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)